PUBLIC COMPANY
saveINTRABIO
USupdated 3mo ago
community read0 votes
pipeline
0
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(0)
no pipeline products on record
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
🐶 Hiring Signal
News
- Genmab and AbbVie’s Epkinly win, a rush of deals, Sarepta’s turnaround hopes, moreNew data for Genmab and AbbVie’s bispecific antibody Epkinly wowed analysts and could set the partners up for an expanded approval in diffuse large B cell lymphoma; deals have flowed steadily this…biospace · 1mo ago
- STAT+: AstraZeneca opens new Boston siteAstraZeneca opened a new R&D site in Kendall Square yesterday, celebrating a $1 billion investment in the unsettled center of U.S. biotechnology after a spate of Chinese dealmaking.stat · 1mo ago
- Shionogi makes $2B rare disease play with IntraBio buyWith its acquisition of IntraBio, Shionogi will gain ownership over Aqneursa, which could hit peak global sales of $1 billion across its two indications in Niemann-Pick disease type C and ataxia-te…biospace · 1mo ago
- Shionogi pays $2B to acquire a rare disease startupThe acquisition of Texas-based IntraBio adds to a growing rare disease business for Shionogi by handing the company a marketed treatment for two inherited conditions.biopharma_dive · 1mo ago
- Shionogi to pay $2B for IntraBio, a commercial rare disease biotechShionogi is buying an Austin, TX-based commercial biotech for $2 billion upfront, adding another medicine to the Japanese pharma's rare disease portfolio. The drugmaker is scooping up IntraBio and…endpoints · 1mo ago
- FDA approves ataxia-telangiectasia drug; Alkermes reports ADHD dataPlus news about Biokin, Bristol Myers Squibb, Grünenthal and Johnson & Johnson. FDA approves ataxia-telangiectasia treatment: The agency approved the rare genetic disease treatment Aqneursa from th…endpoints · 1mo ago
comments(0)
5-min edit window · permanent after that